Comparative Pharmacology
Head-to-head clinical analysis: TESTOSTERONE PROPIONATE versus TLANDO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TESTOSTERONE PROPIONATE versus TLANDO.
TESTOSTERONE PROPIONATE vs TLANDO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone propionate is a short-acting androgen receptor agonist. It binds to androgen receptors, leading to activation of androgen-responsive genes and promotion of male secondary sexual characteristics, anabolic effects, and erythropoiesis.
TLANDO (testosterone undecanoate) is an androgen that binds to and activates androgen receptors, leading to increased protein synthesis, muscle mass, bone density, and secondary sexual characteristics. Testosterone is converted to dihydrotestosterone (DHT) via 5α-reductase in target tissues, exerting both androgenic and anabolic effects.
50-400 mg intramuscularly every 2-4 weeks. For androgen replacement, 50-100 mg IM every 2 weeks.
TLANDO (testosterone undecanoate) is administered orally. The recommended adult dose is 225 mg twice daily (approximately every 12 hours) with a meal containing fat. Swallow capsules whole; do not chew or crush.
None Documented
None Documented
Clinical Note
moderateTestosterone propionate + Tranylcypromine
"The risk or severity of adverse effects can be increased when Testosterone propionate is combined with Tranylcypromine."
Clinical Note
moderateTestosterone propionate + Procarbazine
"The risk or severity of adverse effects can be increased when Testosterone propionate is combined with Procarbazine."
Clinical Note
moderateTestosterone propionate + Pirlindole
"The risk or severity of adverse effects can be increased when Testosterone propionate is combined with Pirlindole."
Clinical Note
moderateTerminal half-life: 0.8–1.2 hours (rapid elimination due to short ester chain; requires frequent dosing).
The terminal elimination half-life of testosterone is 10-100 minutes; however, for TLANDO (testosterone undecanoate) after oral administration, the apparent half-life is approximately 7-10 hours due to the slow release from chylomicrons and prolonged absorption.
Renal: 90% (as glucuronide and sulfate conjugates); Fecal/Biliary: 10%.
Approximately 90% of a dose is excreted in urine as glucuronide and sulfate conjugates of testosterone and its metabolites; about 6% is excreted in feces via bile. Unchanged testosterone accounts for less than 1% of urinary excretion.
Category D/X
Category C
Androgen
Androgen/hormone replacement
Testosterone propionate + Moclobemide
"The risk or severity of adverse effects can be increased when Testosterone propionate is combined with Moclobemide."